Importantly, these secondary MMR-deficient IDH-mutant gliomas do not display an aberrant DNA methylation profile compared to MMR-proficient conventional IDH-mutant astrocytomas. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).